MedKoo Biosciences

Terizidone
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328068

CAS#: 25683-71-0

Description: Terizidone is a drug used in the treatment of tuberculosis. Terizidone is used mainly used in multi-drug-resistant tuberculosis (MDR-TB) in conjunction with other second-line drugs. It is a derivate of cycloserine and it is bacteriostatic.

Chemical Structure

Terizidone

CAS# 25683-71-0

Instruction

Theoretical Analysis

MedKoo Cat#: 328068
Name: Terizidone
CAS#: 25683-71-0
Chemical Formula: C14H14N4O4
Exact Mass: 302.10
Molecular Weight: 302.290
Elemental Analysis: C, 55.63; H, 4.67; N, 18.53; O, 21.17

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 450
200mg	USD 650
500mg	USD 950
1g	USD 1450
2g	USD 2150
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Terizidone

IUPAC/Chemical Name: 4,4'-(((1E,1'E)-1,4-phenylenebis(methanylylidene))bis(azanylylidene))bis(isoxazolidin-3-one)

InChi Key: ODKYYBOHSVLGNU-IAGONARPSA-N

InChi Code: InChI=1S/C14H14N4O4/c19-13-11(7-21-17-13)15-5-9-1-2-10(4-3-9)6-16-12-8-22-18-14(12)20/h1-6,11-12H,7-8H2,(H,17,19)(H,18,20)/b15-5+,16-6+

SMILES Code: O=C1NOCC1/N=C/C2=CC=C(/C=N/C3C(NOC3)=O)C=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 302.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Hwang TJ, Wares DF, Jafarov A, Jakubowiak W, Nunn P, Keshavjee S. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis. 2013 Oct;17(10):1257-66. doi: 10.5588/ijtld.12.0863. Review. PubMed PMID: 23735593.

2: Vora A. Terizidone. J Assoc Physicians India. 2010 Apr;58:267-8. PubMed PMID: 21046890.

3: Galietti F, Giorgis GE, Oliaro A, Boaro D, Ardizzi A, Barberis S, Massaglia GM. [Tolerability to terizidone (TZ) in the treatment of pulmonary tuberculosis in dialyzed patients]. Minerva Med. 1991 Jul-Aug;82(7-8):477-81. Italian. PubMed PMID: 1922892.

4: Semenitz E, Madersbacher H, Spanudakis S. [Contribution to the therapeutic use of terizidone]. Wien Med Wochenschr. 1976 Nov 5;126(45):640-2. German. PubMed PMID: 1007295.

5: Costa AL. [Antibacterial activity of urea combined with terizidone on pathogenic strains isolated from urine cultures]. Minerva Urol. 1976 May-Jun;28(3):109-11. Italian. PubMed PMID: 1018703.

6: Zítková L, Tousek J. Pharmacokinetics of cycloserine and terizidone. A comparative study. Chemotherapy. 1974;20(1):18-28. PubMed PMID: 4845674.

7: Pavlík V, Hradecký L. [Terizidone and phenazopyridine--an effective preparation for treatment of infections of the urinary tract during pregnancy (author's transl)]. Cesk Gynekol. 1973 Nov;38(9):660-1. Czech. PubMed PMID: 4765157.

8: Böszörményi M. [Triple placebo test for comparison of side effects of terizidone (terivalidin) and cycloserine]. Int J Clin Pharmacol. 1973 Aug;8(1):37-41. German. PubMed PMID: 4580381.

9: Zrilić V, Mijatović M, Mirković S, Muzikravić T. [Results of clinical trials of a new antitubercular agent, terizidone (Terivalidine)]. Plucne Bolesti Tuberk. 1972 Apr-Jun;24(2):89-98. . PubMed PMID: 4565191.

10: Dumon JF, Aimone J, Dumon G. [Preliminary note on Terizidone]. Mars Med. 1972;109(11):730-2. French. PubMed PMID: 4662237.

11: Strata A. [Clinical pharmacology of Terizidone]. Lotta Tuberc. 1971 Aug-Sep;41(3):367-88. Italian. PubMed PMID: 5003852.

12: Fossati C. [Terizidone in the therapy of chronic pulmonary tuberculosis]. G Ital Mal Torace. 1971 Jul-Aug;25(4):195-204. Italian. PubMed PMID: 5141834.

13: Robutti A. [Terizidone in the therapy of urogenital tuberculosis]. Minerva Urol. 1971 Jul-Aug;23(4):139-48. Italian. PubMed PMID: 5117333.

14: Gaĭdov N. [Terizidone--a new synthetic antitubercular antibiotic (review of the literature)]. Probl Tuberk. 1971;49(12):19-22. Review. Russian. PubMed PMID: 4946049.

15: Briones FH. [Evaluation of secondary manifestations in patients treated with terizidone]. Rev Bras Med. 1970 May;27(5):271-5. Portuguese. PubMed PMID: 5457765.

16: Hammerli A, Gallindo IS. [Treatment of resistant chronic tuberculosis. A new antitubercular agent: terizidone]. Rev Bras Med. 1969 Nov;26(11):684-8. Portuguese. PubMed PMID: 5396432.

17: Nitti V, Catena E, Ninni A, Marsico SA. [Activity of terizidone in experimental tuberculosis in rabbits]. Arch Tisiol Mal Appar Respir. 1969 Sep;24(9):667-98. Italian. PubMed PMID: 5315045.

18: Strata A, Dell'Anna A, Cucurachi P, Borghetti A, Novarini A, Franchini I. [Pharmacokinetics of Terizidone in kidney diseases patients]. G Clin Med. 1969 Jun;50(6):504-20. Italian. PubMed PMID: 5386608.

19: Rizzo A, Gomes A, Antunes G. [Cycloserine and terizidone in the treatment of pulmonary tuberculosis: clinical study of tolerance]. Rev Bras Med. 1969 Feb;26(2):119-22. Portuguese. PubMed PMID: 5797682.

20: Vivenzio L. [Terizidone in the therapy of tubercular orchiepididymitis]. Arch Tisiol Mal Appar Respir. 1968 Dec;23(12):1001-6. Italian. PubMed PMID: 5305705.

Your view history

Terizidone featured